期刊文献+
共找到438篇文章
< 1 2 22 >
每页显示 20 50 100
Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12 被引量:2
1
作者 Jianhui Nie Juan Zhao +2 位作者 Qingqing Chen Weijin Huang Youchun Wang 《Virologica Sinica》 SCIE CAS CSCD 2014年第5期299-307,共9页
The CD4 binding site(CD4bs) of envelope glycoprotein(Env) is an important conserved target for anti-human immunodeficiency virus type 1(HIV-1) neutralizing antibodies. Neutralizing monoclonal antibodies IgG1 b12(b12) ... The CD4 binding site(CD4bs) of envelope glycoprotein(Env) is an important conserved target for anti-human immunodeficiency virus type 1(HIV-1) neutralizing antibodies. Neutralizing monoclonal antibodies IgG1 b12(b12) could recognize conformational epitopes that overlap the CD4 bs of Env. Different virus strains, even derived from the same individual, showed distinct neutralization susceptibility to b12. We examined the key amino acid residues affecting b12 neutralization susceptibility using single genome amplification and pseudovirus neutralization assay. Eleven amino acid residues were identified that affect the sensitivity of Env to b12. Through site-directed mutagenesis, an amino acid substitution at position 182 in the V2 region of Env was confirmed to play a key role in regulating the b12 neutralization susceptibility. The introduction of V182 L to a resistant strain enhanced its sensitivity to b12 more than twofold. Correspondingly, the introduction of L182 V to a sensitive strain reduced its sensitivity to b12 more than tenfold. Amino acid substitution at positions 267 and 346 could both enhance the sensitivity to b12 more than twofold. However, no additive effect was observed when the three site mutageneses were introduced into the same strain, and the sensitivity was equivalent to the single V182 L mutation. CRF07_BC is a major circulating recombinant form of HIV-1 prevalent in China. Our data may provide important information for understanding the molecular mechanism regulating the neutralization susceptibility of CRF07_BC viruses to b12 and may be helpful for a vaccine design targeting the CD4 bs epitopes. 展开更多
关键词 human immunodeficiency virus type 1 CRF07_BC ENVELoPE GLYCoPRoTEIN IgG1b12 NEUTRALIZING antibody single genome amplification
下载PDF
Cost and safety of assisted reproductive technologies for human immunodeficiency virus-1 discordant couples 被引量:1
2
作者 Ming-Yih Wu Hong-Nerng Ho 《World Journal of Virology》 2015年第2期142-146,共5页
Due to significant advances in the treatment of human immunodeficiency virus type-1(HIV-1), HIV-1 infection gradually has become a treatable chronic disease. Successfully treated HIV-positive individuals can have a no... Due to significant advances in the treatment of human immunodeficiency virus type-1(HIV-1), HIV-1 infection gradually has become a treatable chronic disease. Successfully treated HIV-positive individuals can have a normal life expectancy. Hence, more and more HIV-1 discordant couples in Taiwan and the rest of the world are seeking fertility assistance. Pre-treatment of highly active antiretroviral therapy(HAART) combined with sperm washing and RT-polymerase chain reaction examination for HIV-1 viral load has become the standard procedure to assist them to conceive. However,in order to reduce the transmission risk to the lowest level for the couple and to diminish the cost of health care for the insurance institutes or government, in vitro fertilization(IVF)-intracytoplasmic sperm injection(ICSI) therapy provides the ideal solution for HIV-1 discordant couples with infected men. Intrauterine insemination(IUI) theoretically introduces more than 107 times of sperm counts or semen volume to uninfected women vs IVF-ICSI. However, since some regimens of HAART may significantly decrease the sperm motility, compared to IVF-ICSI, IUI only produces 1/5 to 1/2 pregnancy rates per cycle. Given the risk of seroconversion of HIV infection which actually happens after successful treatment, IVF-ICSI for these HIV-1 seropositive men is more cost-effective and should be the first line treatment for these cases. 展开更多
关键词 Highly active ANTIRETRoVIRAL therapy human immunodeficiency virus-1 DISCoRDANT SERoCoNVERSIoN INTRAUTERINE INSEMINATIoN INTRACYToPLASMIC sperm injection
下载PDF
Construction and expression of an optimized, novel human immunodeficiency virus type-1 lentiviral vector containing green fluorescent protein
3
作者 Xia Li Xueling Ma +6 位作者 Lijing Zhao Hang Gao Hongjuan Wang Li Du1 Juan Wang Nan Li Kangding Liu 《Neural Regeneration Research》 SCIE CAS CSCD 2011年第7期542-545,共4页
The human immunodeficiency virus (HIV) lentiviral vector is an ideal vector for gene therapy. In the present study, the wild-type HIV-1 genome was segregated into four plasmids, and an optimized novel HIV-1 lentivir... The human immunodeficiency virus (HIV) lentiviral vector is an ideal vector for gene therapy. In the present study, the wild-type HIV-1 genome was segregated into four plasmids, and an optimized novel HIV-1 lentiviral vector containing green fluorescent protein and vesicular stomatitis virus G pseudo-capsule was constructed. The plasmids were pHR-CMV-EGFP, pCMVΔ8.9, pRSV-Rev, pCMV-VSV-G. The four plasmid system was co-transfected into 293T cells, and green fluorescent protein expression was observed. The present study obtained lentiviral particles by high-speed centrifugation, and the lentiviral particle titer was 4 × 108 TU/mL after centrifugation. Thus, an optimized novel HIV-1 lentiviral vector was successfully constructed. 展开更多
关键词 gene expression gene therapy human immunodeficiency virus 1 green fluorescent protein LENTIvirus neural regeneration
下载PDF
INTRACELLULAR EXPRESSION OF MULTIMERIZED ANTISENSE TAR-CORE RNAS INHIBIT THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN HUMAN CD_4+T LYMPHOCYTES
4
作者 白龙川 袁建刚 +3 位作者 杜光伟 赵全璧 邵一鸣 强伯勤 《Chinese Medical Sciences Journal》 CAS CSCD 1999年第1期13-16,共4页
Gene therapy is one of several approaches that are being tested in the search for an effective anti HIV treatment. In this strategy, a “resistant” gene would be introduced into target ... Gene therapy is one of several approaches that are being tested in the search for an effective anti HIV treatment. In this strategy, a “resistant” gene would be introduced into target cells, rendering them resistance to the infection of HIV. The HIV 1 Tat protein transactivate HIV 1 gene expression at the transcriptional level by interacting with its response element(TAR) in the long terminal repeat(LTR). Previously, we have shown that antisense polyTAR Core RNAs can inhibit the transactivation of HIV 1 Tat protein in transiently transfected Jurkat cells. To determine whether this antisense polyTAR Core RNAs could inhibit HIV 1 replication in CD 4+ T cells, we transfected the antisense polyTAR Core gene to MT4 cells and challenged them with HIV 1 SF33 strain. Levels of HIV 1 p24gag antigen were reduced more than 4 fold in cultures of the transduced MT4/LR cells infected with HIV 1SF33 strain. In contrast, cultures of nontransduced MT4 cells and control LX vector transduced MT4/LX cells infected with the same viruses had high levels of HIV 1 p24gag. Our work showed that antisense polyTAR Core RNAs were able to inhibit HIV 1 replication in CD 4+ T cells, and could be used as resistance gene in further studying for gene therapy against HIV 1. 展开更多
关键词 human immunodeficiency virus type 1(HIV 1) TAR Tat gene therapy
下载PDF
The Value of Support Group Participation in Influencing Adherence to Antiretroviral Treatment among People Living with Human Immunodeficiency Virus (HIV)
5
作者 Simpson Tumwikirize Kwasi Torpey +1 位作者 Oluwasanmi Adedokun Tilitope Badru 《World Journal of AIDS》 2015年第3期189-198,共10页
Advances in antiretroviral therapy for both Human Immunodeficiency Virus (HIV) treatment and prevention have increased interest in adherence to HIV treatment. This is because the individual patient and public health b... Advances in antiretroviral therapy for both Human Immunodeficiency Virus (HIV) treatment and prevention have increased interest in adherence to HIV treatment. This is because the individual patient and public health benefits of antiretroviral treatment?(ART) greatly depend on the extent to which people living with HIV (PLHIV) adhere to the prescribed daily dosing regimens. Studies have shown that nonadherence to ART increases drug resistance, morbidity and person-to-person HIV transmission. Public health experts are trying different innovations to enhance ART adherence, including promoting support groups of PLHIV. The purpose of this study was to determine the value of support group participation in enhancing ART adherence. The study used a cross-sectional design to compare ART adherence among PLHIV who participate in support group activities and those who do not. Respondents were adults who were initiated on ART between January 1, 2010 and December 31, 2012. Multistage probability sampling was used to select study sites and respondents. Data was collected using a self-administered questionnaire from 1676 respondents between February and May 2014. Data was analyzed using STATA. Univariate analysis was carried out to generate descriptive statistics, while Chi-square tests were used to examine if there was an association between participation in support group activities and antiretroviral treatment adherence. ART adherence was self-reported by 745/788 (95%) and 814/888 (92%) respondents who had ever and had never participated in support group activities respectively. Among respondents who reported nonadherence to ART, 74/117 (8%) had never participated in support group activities compared to just 43/117 (5%) who participated in support group activities. These findings suggest that PLHIV who participate in support group activities are more likely to adhere to ART than those who do not participate. This implies that there is value in participating in support groups by PLHIV in terms of ART adherence. 展开更多
关键词 Support groupS human immunodeficiency virus PARTICIPATIoN ANTIRETRoVIRAL Therapy ADHERENCE
下载PDF
Improvement in human immunodeficiency virus-1/acquired immune deficiency syndrome patients' well-being following administration of “Phyto V7”
6
作者 Ruben Wernik Jose L Priore +2 位作者 Walter F Goldman Adriana del Carmen Elias Gadi Borkow 《World Journal of Clinical Infectious Diseases》 2015年第2期44-50,共7页
AIM:To corroborate the capacity of Phyto V7,a complex of phytochemicals,to improve the physical well-being of human immunodeficiency virus-1(HIV-1) infected and acquired immune deficiency syndrome(AIDS) patients not u... AIM:To corroborate the capacity of Phyto V7,a complex of phytochemicals,to improve the physical well-being of human immunodeficiency virus-1(HIV-1) infected and acquired immune deficiency syndrome(AIDS) patients not undergoing antiretroviral treatment.METHODS:Two hundred and thirty nine HIV-1 seropositive male and female voluntary inmates were recruited through the Uruguay National Program of AIDS.The study participants received for 90 consecutive days every eight hours two tablets(760 mg/each) of Phyto V7,containing a mix of the following phytochemicals:flavonols(Kaempferol,Quercetin),flavones(Apigenin,Luteolin),hydroxycinnamic acids(ferrulic acid),carotenoids(Lutein,Lycopene,Beta carotene) and organosulfur compounds,all from vegetal origin.The participants did not receive any antiretroviral treatment during the study.At days 0,30,60 and 90(± 2 d) the participants were evaluated for body mass index(BMI),tolerance to Phyto V7 and Index of Quality of Life based on the Karfnosky scale.ANOVA,Tukey Post-test,χ2 test and Wilcoxon Signed Rank test were used to analyze the effect of treatment.RESULTS:One hundred and nighty nine study participants finished the study.Already after 30 d of Phyto V7 consumption,the weight,BMI and Karnofsky score statistically significantly improved(P < 0.001),and continued to improve until the end of the study.The mean weight gain per participant during the 90 d wasof 1.21 kg(approximately 2% of body weight).The overall increase in the mean Karnofsky score after 90 d was 14.08%.The lower the BMI and Karnofsky score of the participants were at the beginning of the study,the more notorious was the improvement over time.For example,the mean increment of Index of Quality of Life,among the participants with an initial Karnofsky score of 5 or below(n = 33) from day 0 to day 90,was of 35.67%(0.476 ± 0.044 vs 0.645 ± 0.09; P < 0.001).The tolerability to Phyto V7 was very good and no adverse reactions were recorded or reported.CONCLUSION:Administration of the Phyto V7 can be an important tool to improve the well-being of HIV-1 seropositive individuals and AIDS patients,not undergoing antiretroviral treatment. 展开更多
关键词 PHYToCHEMICALS Karnofsky score Nutrition human immunodeficiency virus-1 ACQUIRED immune DEFICIENCY syndrome
下载PDF
The role of monocyte-lineage cells in human immunodeficiency virus persistence: mechanisms and progress 被引量:1
7
作者 WU Li 《微生物与感染》 2011年第3期129-132,共4页
Human immunodeficiency virus type 1(HIV-1) persistence is a major barrier to the successful treatment and eradication of acquired immunodeficiency syndrome(AIDS).In addition to resting CD4+ T cells,a significant long-... Human immunodeficiency virus type 1(HIV-1) persistence is a major barrier to the successful treatment and eradication of acquired immunodeficiency syndrome(AIDS).In addition to resting CD4+ T cells,a significant long-lived compartment of HIV-1 infection in vivo includes blood monocytes and tissue macrophages.Studying HIV-1 persistence in monocyte-lineage cells is critical because these cells are important HIV-1 target cells in vivo.Monocyte-lineage cells,including monocytes,dendritic cells(DCs) and macrophages,play a significant role in HIV-1 infection and transmission.These cells have been implicated as viral reservoirs that facilitate HIV-1 latency and persistence.A better understanding of HIV-1 interactions with monocyte-lineage cells can potentially aid in the development of new approaches for intervention.This minireview highlights the latest advances in understanding the role of monocyte-lineage cells in HIV-1 persistence and emphasizes new insights into the mechanisms underlying viral persistence. 展开更多
关键词 摘要 编辑部 编辑工作 读者
下载PDF
Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus
8
作者 Catalina Méndez Chantelle L Ahlenstiel Anthony D Kelleher 《World Journal of Virology》 2015年第3期219-244,共26页
While human immunodeficiency virus 1(HIV-1) infectionis controlled through continuous, life-long use of a combination of drugs targeting different steps of the virus cycle, HIV-1 is never completely eradicated from th... While human immunodeficiency virus 1(HIV-1) infectionis controlled through continuous, life-long use of a combination of drugs targeting different steps of the virus cycle, HIV-1 is never completely eradicated from the body. Despite decades of research there is still no effective vaccine to prevent HIV-1 infection. Therefore, the possibility of an RNA interference(RNAi)-based cure has become an increasingly explored approach. Endogenous gene expression is controlled at both, transcriptional and post-transcriptional levels by noncoding RNAs, which act through diverse molecular mechanisms including RNAi. RNAi has the potential to control the turning on/off of specific genes through transcriptional gene silencing(TGS), as well as finetuning their expression through post-transcriptional gene silencing(PTGS). In this review we will describe in detail the canonical RNAi pathways for PTGS and TGS, the relationship of TGS with other silencing mechanisms and will discuss a variety of approaches developed to suppress HIV-1 via manipulation of RNAi. We will briefly compare RNAi strategies against other approaches developed to target the virus, highlighting their potential to overcome the major obstacle to finding a cure, which is the specific targeting of the HIV-1 reservoir within latently infected cells. 展开更多
关键词 human immunodeficiency virus 1 RNA interference Reservoirs EPIGENETICS Latency TRANSCRIPTIoNAL GENE SILENCING PoST-TRANSCRIPTIoNAL GENE SILENCING
下载PDF
A Human T Lymphotropic Virus Type 1 Carrier Coinfected with <i>Mycobacterium intracellulare</i>and <i>Pneumocystis jirovecii</i>with a Characteristic Compositional Change of Bone Marrow Cells
9
作者 Sayaka Uda Shinsuke Shiotsu +10 位作者 Ayaka Omura Ryosuke Hamashima Akihiro Yoshimura Naoko Kurisu Tomoya Sagawa Koichi Hasegawa Tatsuya Yuba Chieko Takumi Seiko Ono Noriya Hiraoka Noriya Hiraoka 《Open Journal of Respiratory Diseases》 2017年第3期110-116,共7页
Human T lymphotropic virus type 1 (HTLV-1) is endemic in the southern part of Japan. Infection of the virus can cause adult T cell leukemia/lymphoma (ATL), while most infected individuals remain in a carrier state for... Human T lymphotropic virus type 1 (HTLV-1) is endemic in the southern part of Japan. Infection of the virus can cause adult T cell leukemia/lymphoma (ATL), while most infected individuals remain in a carrier state for a long period of time. Although rare cases of carriers, like ATL patients, who developed opportunistic infections, have been reported, hematological changes of carriers who are prone to opportunistic infections have not been well defined. Here, we present a case of an HTLV-1 carrier who developed Mycobacterium intracellulare infection and Pneumocystis jirovecii pneumonia (PcP) simultaneously. Flow cytometric analysis of bone marrow cells revealed an aberrant compositional change similar to that in ATL patients. This suggests the presence of a pre-ATL state prior to the development of ATL, which is notable in terms of underlying cellular immunodeficiency. 展开更多
关键词 human T Lymphotropic virus TYPE 1 CARRIER immunodeficiency Pneumocystis jirovecii
下载PDF
HIV-1整合酶基因序列分析方法验证
10
作者 王绪琴 林倩茹 +7 位作者 冯琬清 董原 郁晓磊 刘长河 宁镇 沈鑫 潘启超 林怡 《检验医学》 CAS 2024年第4期369-375,共7页
目的 验证实验室自建人类免疫缺陷病毒1型(HIV-1)整合酶基因序列分析方法。该方法可用于评估HIV-1整合酶区段基因型耐药水平。方法 根据世界卫生组织自建基因序列分析方法验证的建议,从20份HIV-1阳性样本中提取RNA,扩增HIV-1整合酶区基... 目的 验证实验室自建人类免疫缺陷病毒1型(HIV-1)整合酶基因序列分析方法。该方法可用于评估HIV-1整合酶区段基因型耐药水平。方法 根据世界卫生组织自建基因序列分析方法验证的建议,从20份HIV-1阳性样本中提取RNA,扩增HIV-1整合酶区基因片段,并测序。通过与病毒质量保证(VQA)共识进行比对,评估实验室自建的HIV-1整合酶基因序列分析方案的准确性,通过扩增成功率评估其灵敏度,通过同一样本的重复检测结果评估其精密度和重现性。结果 20份样本与VQA共识的核苷酸一致率均>98%;10个高病毒载量(>10 000拷贝·mL^(-1))样本和5个低病毒载量(1 000~5 000拷贝·mL^(-1))样本的扩增成功率均为100%;4个样本的同批次5复孔和5个样本5次检测的结果均符合90%的样本配对比较核苷酸一致率>98%的要求。结论 该HIV-1整合酶基因序列分析方法的准确性、灵敏度、精密度和重现性均符合要求,适用于HIV-1整合酶基因序列分析。 展开更多
关键词 人类免疫缺陷病毒1 整合酶基因序列分析 基因型耐药检测
下载PDF
坏死性凋亡与HIV-1感染的研究进展
11
作者 徐志良 韦吴迪 +2 位作者 叶力 梁浩 赖菁贞 《广西医科大学学报》 CAS 2024年第5期786-790,共5页
由于人类免疫缺陷病毒1型(HIV-1)在细胞中形成潜伏感染,且HIV-1潜伏感染机制尚不明确,导致当前抗逆转录病毒治疗无法根除感染者体内的HIV-1。坏死性凋亡作为一种受调控的细胞死亡形式,可在HIV-1感染的多种免疫细胞中发生,同时HIV-1可通... 由于人类免疫缺陷病毒1型(HIV-1)在细胞中形成潜伏感染,且HIV-1潜伏感染机制尚不明确,导致当前抗逆转录病毒治疗无法根除感染者体内的HIV-1。坏死性凋亡作为一种受调控的细胞死亡形式,可在HIV-1感染的多种免疫细胞中发生,同时HIV-1可通过抑制细胞内坏死相关信号通路逃避细胞死亡的宿命,有利于为病毒潜伏库的形成。此外,坏死性凋亡主要发生在HIV-1感染的细胞中,不会造成近旁未感染细胞的损伤,可能成为靶向清除HIV潜伏库的潜在靶点。本文围绕坏死性凋亡在HIV-1感染细胞中的发生情况和相关机制进行综述,以期为后续开展HIV-1潜伏感染相关机制研究提供参考。 展开更多
关键词 人类免疫缺陷病毒1 潜伏感染 坏死性凋亡 细胞死亡
下载PDF
广西崇左市扶绥县HIV-1分子传播网络特征分析
12
作者 何锦锋 李牧 +9 位作者 覃雪秋 黄玲芳 区艳芸 农爱丹 黄英贵 白永刚 邹华春 张伟杰 包丽娟 梁冰玉 《广西医科大学学报》 CAS 2024年第6期918-925,共8页
目的:分析广西崇左市扶绥县艾滋病病毒(HIV)感染者的分子传播网络特征,并确定造成分子网络聚簇传播和高风险传播的危险因素。方法:采集崇左市扶绥县2005—2021年确诊的HIV/艾滋病(AIDS)患者血样。通过扩增HIV-1 pol区序列比对分析,构建... 目的:分析广西崇左市扶绥县艾滋病病毒(HIV)感染者的分子传播网络特征,并确定造成分子网络聚簇传播和高风险传播的危险因素。方法:采集崇左市扶绥县2005—2021年确诊的HIV/艾滋病(AIDS)患者血样。通过扩增HIV-1 pol区序列比对分析,构建分子传播网络。运用二元logistic回归分析入网和高危传播的影响因素。结果:本研究共获得扶绥县349条HIV-1 pol区序列,6种亚型,分别为CRF01_AE亚型(49.86%)、CRF07_BC亚型(32.38%)、CRF08_BC亚型(14.33%)、CRF55_01B亚型(1.14%)、C亚型(0.29%)、独特重组型(URF)(2.00%)。192条(55.01%)序列进入分子传播网络,形成31个簇、192个节点和736条边。年龄>50岁(a OR=1.861,95%CI:1.009~3.433)、感染CRF07_BC亚型毒株(a OR=4.386,95%CI:2.533~7.594)、文化程度为小学及以下(a OR=1.709,95%CI:1.070~2.729)、有非婚商业异性性接触史(a OR=1.682,95%CI:1.027~2.753),配偶或固定性伴阳性(a OR=2.428,95%CI:1.181~4.995)的患者更容易进入传播网络聚簇传播。年龄>50岁(a OR=1.861,95%CI:1.009~3.433),感染CRF07_BC亚型(a OR=4.386,95%CI:2.533~7.594),文化程度为小学及以下(a OR=1.699,95%CI:1.004~2.874)的患者更容易成为传播网络中的高连接者。结论:广西崇左市扶绥县AIDS传播的关键人群是年龄>50岁且文化程度为小学及以下的中老年人群,应针对重点人群的在分子网络中的传播聚簇特点进行溯源调查,并实施精准干预,减少二代传播。 展开更多
关键词 艾滋病病毒-1 分子传播网络 高危传播者 影响因素
下载PDF
水芹总酚酸体外抗HIV-1的作用
13
作者 黄紫晴 于珊 +2 位作者 黄正明 马丽英 刘青川 《解放军药学学报》 CAS 2024年第1期25-28,共4页
目的探讨水芹总酚酸体外抑制人类免疫缺陷病毒1型的作用。方法用不同稀释度的水芹总酚酸与TZM-bl细胞共同培养,使用MTT法检测活细胞的数量,观察水芹总酚酸对TZM-bl细胞的毒性作用;用人类免疫缺陷病毒1型实验室适应株SF33、BAL分别感染TZ... 目的探讨水芹总酚酸体外抑制人类免疫缺陷病毒1型的作用。方法用不同稀释度的水芹总酚酸与TZM-bl细胞共同培养,使用MTT法检测活细胞的数量,观察水芹总酚酸对TZM-bl细胞的毒性作用;用人类免疫缺陷病毒1型实验室适应株SF33、BAL分别感染TZM-bl细胞,基于TZM-bl细胞的荧光素酶检测体系,采用荧光素酶活性检测方法检测水芹总酚酸抗人类免疫缺陷病毒1型的活性。结果水芹总酚酸对TZM-bl细胞表现出较低的细胞毒性,半数细胞毒浓度>1600μg·ml^(-1)。水芹总酚酸对TZM-bl细胞HIV-1 SF33、HIV-1 BAL病毒的半抑制浓度平均值分别为38.93和24.25μg·ml^(-1),治疗指数分别为>41和>66。结论水芹总酚酸在体外具有抑制人类免疫缺陷病毒1型复制活性的作用。 展开更多
关键词 水芹总酚酸 人类免疫缺陷病毒1 抗病毒活性
下载PDF
SerpinE1通过JAK/STAT通路调节HIV-1在巨噬细胞中的复制
14
作者 陆贝贝 陈姗姗 +6 位作者 陈飞蓉 石敏娟 吴玉婷 叶力 梁浩 苏锦明 蒋俊俊 《广西医科大学学报》 CAS 2024年第6期826-832,共7页
目的:探讨丝氨酸蛋白酶抑制剂E家族成员1(SerpinE1)与人类免疫缺陷病毒1型(HIV-1)感染的关系,及其作为一种蛋白酶抑制剂在巨噬细胞中对HIV感染过程发挥的作用和机制。方法:按年龄、性别特征成组匹配,招募HIV感染未治疗人群[HIV ART(-)组... 目的:探讨丝氨酸蛋白酶抑制剂E家族成员1(SerpinE1)与人类免疫缺陷病毒1型(HIV-1)感染的关系,及其作为一种蛋白酶抑制剂在巨噬细胞中对HIV感染过程发挥的作用和机制。方法:按年龄、性别特征成组匹配,招募HIV感染未治疗人群[HIV ART(-)组]和健康对照人群(HC组),并检测外周血单个核细胞(PBMCs)中SerpinE1 mRNA表达量。在THP-1细胞中构建SerpinE1敲低细胞(敲低SerpinE1组),感染或不感染HIV BaL。酶联免疫吸附试验(ELISA)法检测HIV-p24和干扰素(IFN)-α蛋白水平,有参转录组测序分析染毒后敲低SerpinE1组与对照组的差异基因和KEGG富集通路,实时荧光定量PCR(RT-qPCR)法检测HIV-1 Gag、Toll样受体7(TLR7)、Toll样受体8(TLR8)、白细胞介素-1β(IL-1β)、MX动力蛋白样GTPase 1(MX1)、MX动力蛋白样GTPase 2(MX2)mRNA相对表达量,western blotting法检测JAK2、STAT1、STAT2、SATA4、IL-1β和MX1蛋白表达水平。结果:与HC组比较,HIV ART(-)组SerpinE1表达水平降低,并且在THP-1来源的巨噬细胞中能够被HIV诱导下调(P<0.05);敲低SerpinE1表达下调HIV-p24蛋白表达和HIV Gag mRN A表达,促进IFN-α蛋白分泌水平,促进TLR7、TLR8、Janus激酶2(JAK2)、信号转导子和转录激活子(STAT)蛋白家族的STAT1、STAT2、SATA4及IL-1β、MX1、MX2的表达(P<0.05)。结论:SerpinE1可能通过抑制TLR7和TLR8信号通路的激活,减少IFN-α的释放,进而抑制JAK/STAT通路及其诱导的多种IFN刺激基因和IFN相关因子表达,从而促进了HIV-1的感染复制。 展开更多
关键词 丝氨酸蛋白酶抑制剂E家族成员1 巨噬细胞 干扰素-Α JAK/STAT 抗人类免疫缺陷病毒1
下载PDF
宫颈癌及癌前病变宫颈组织中miR-34a-5p和HMGB1表达及与HPV感染的相关性
15
作者 周立飞 高跃丽 +4 位作者 耿欣 张静亚 耿飞龙 康非 王亚凡 《河北医药》 CAS 2024年第13期1946-1949,1954,共5页
目的 探讨微小RNA-34a-5p(miR-34a-5p)、高迁移率族蛋白B1(HMGB1)在宫颈癌(CC)及癌前病变患者表达水平及二者与人乳头状瘤病毒(HPV)感染的关系。方法 回顾性分析2018年1月至2022年6月诊治的165例宫颈手术标本,其中CC 55例(CC组),癌前病... 目的 探讨微小RNA-34a-5p(miR-34a-5p)、高迁移率族蛋白B1(HMGB1)在宫颈癌(CC)及癌前病变患者表达水平及二者与人乳头状瘤病毒(HPV)感染的关系。方法 回顾性分析2018年1月至2022年6月诊治的165例宫颈手术标本,其中CC 55例(CC组),癌前病变55例为癌前病变组,正常宫颈组织55例为对照组。检测所有受试者宫颈组织miR-34a-5p、HMGB1表达水平及HPV感染情况;分析CC及宫颈癌前病变患者宫颈组织miR-34a-5p、HMGB1表达水平与HPV感染的关系;生物信息学预测miR-34a-5p与HMGB1的关系,分析CC及宫颈癌前病变患者宫颈组织miR-34a-5p与HMGB1水平的相关性。结果 CC组宫颈组织miR-34a-5p表达水平低于对照组和癌前病变组(P<0.05),HMGB1表达水平、HPV阳性感染率高于对照组和癌前病变组(P<0.05);癌前病变组宫颈组织miR-34a-5p表达水平低于对照组(P<0.05),HMGB1表达水平、HPV阳性感染率高于对照组(P<0.05)。宫颈组织miR-34a-5p表达水平与CC及其癌前病变患者HPV感染呈负相关(P<0.05);宫颈组织HMGB1表达水平与CC及癌前病变患者HPV感染呈正相关(P<0.05)。miR-34a-5p与HMGB1存在结合位点,癌前病变、CC患者宫颈组织miR-34a-5p表达水平均与HMGB1呈负相关(P<0.05)。结论 CC及癌前病变患者宫颈组织miR-34a-5p表达下调,HMGB1表达上调,二者均与HPV感染密切相关。 展开更多
关键词 微小RNA-34a-5p 宫颈癌 高迁移率族蛋白B1 癌前病变 人乳头状瘤病毒
下载PDF
HIV-1/2/O抗体联合诊断试剂盒的制备及其检测效果的研究 被引量:3
16
作者 何国坚 黄震 +1 位作者 张韶斌 陈斯亮 《国际检验医学杂志》 CAS 2011年第5期562-564,共3页
目的制备HIV-1/2/O抗体检测试剂盒并评估其检测效果。方法采用RT-PCR分别获取HIV-1型M、O组的gp41以及HIV-2gp36的优势表位基因,并通过柔性链将各表位基因嵌合,重组表达,亲和纯化、辣根过氧化酶标记,与包被抗原配对筛选,获取检测HIV抗... 目的制备HIV-1/2/O抗体检测试剂盒并评估其检测效果。方法采用RT-PCR分别获取HIV-1型M、O组的gp41以及HIV-2gp36的优势表位基因,并通过柔性链将各表位基因嵌合,重组表达,亲和纯化、辣根过氧化酶标记,与包被抗原配对筛选,获取检测HIV抗体的双抗原试剂。结果成功嵌合各表位基因并获得表达,纯化后的抗原具有很高的抗原活性,检测灵敏度与国外试剂相当。结论采用柔性链技术嵌合表达制备的HIV-1/2/O抗体联合诊断试剂盒对HIVO组病毒株的检测具有较高灵敏度。 展开更多
关键词 HIV o亚型 酶联免疫诊断 柔性链 双抗原夹心
下载PDF
多聚TAR-CoreRNA诱饵对人免疫缺陷病毒1型Tat蛋白活性的抑制作用
17
作者 白龙川 袁建刚 +1 位作者 杜光伟 强伯勤 《中国生物化学与分子生物学报》 CAS CSCD 1998年第5期628-631,共4页
为了抑制Tat蛋白的反式激活作用,在细胞内大量表达外源TARRNA使其与Tat蛋白结合,从而竞争性抑制其与HIV-1LTR的TARRNA元件结合.构建了以HIV-1LTRYL158(-158~+180)为启动子,分别... 为了抑制Tat蛋白的反式激活作用,在细胞内大量表达外源TARRNA使其与Tat蛋白结合,从而竞争性抑制其与HIV-1LTR的TARRNA元件结合.构建了以HIV-1LTRYL158(-158~+180)为启动子,分别含有4,8和15个拷贝的TAR-CoreRNA诱饵(decoy)表达质粒;以荧光酶基因为报告基因,检测了瞬时共转染体系中含不同拷贝数的TAR-CoreDNA转录产物对Tat蛋白反式激活作用的影响.结果证明,TAR-CoreRNA诱饵对Tat蛋白活性具有很强的抑制作用,其抑制程度与TAR-CoreDNA串联体的拷贝数有关. 展开更多
关键词 人免疫缺陷病毒 TAT TAR-Core RNA 诱饵
下载PDF
Bilateral Peripheral Facial Paralysis Combined with HIV Meningitis During Acute HIV-1 Infection: A Case Report 被引量:1
18
作者 吴焱 宋歌 +1 位作者 魏春波 伦文辉 《Chinese Medical Sciences Journal》 CAS CSCD 2019年第1期55-59,共5页
Here we reported a Chinese case of bilateral peripheral facial paralysis(PFP) in human immunodeficiency virusc(HIV) infected population. A 38-year-old homosexual male patient was referred to our hospital for bilateral... Here we reported a Chinese case of bilateral peripheral facial paralysis(PFP) in human immunodeficiency virusc(HIV) infected population. A 38-year-old homosexual male patient was referred to our hospital for bilateral facial paralysis. 21 days prior to admission he had developed high fever, chills, headache, fatigue, general malaise, nausea and vomiting. Neurological examination revealed bilateral ptosis of lower lip and cheeks, as well as failure of bilateral eyes closure. Analysis of cerebrospinal fluid(CSF) revealed pleocytosis, a marked rise of micro total protein and a marked rise of intrathecal lgG synthesis. The result of HIV-1 serology was positive by ELISA and that was confirmed by western blot. His CD4^+ cell count was 180 cells/mm^3. HIV-1 viral load in CSF was almost 10 times higher than that in plasma. The patient's condition improved steadily and experienced complete resolution of bilateral PFP after 2 months. 展开更多
关键词 human immunodeficiency virus ACQUIRED immune deficiency syndrome ACUTE human immunodeficiency virus-1 infection peripheral facial PARALYSIS
下载PDF
治疗前血浆和全血干血斑样品HIV-1 Pol区基因型耐药检测结果比较 被引量:2
19
作者 蔡晓莉 范庆红 +3 位作者 兰芸 李丽雅 王瑾琳 陈伟烈 《检验医学与临床》 CAS 2021年第7期893-896,共4页
目的比较治疗前静脉血浆和全血干血斑(DBS)人类免疫缺陷病毒1型(HIV-1)Pol区基因型耐药检测结果的差异,并分析DBS样品用于HIV-1基因型耐药检测的可行性。方法采集44例HIV-1感染者治疗前静脉全血,分别制备全血DBS样品和血浆样品,提取RNA... 目的比较治疗前静脉血浆和全血干血斑(DBS)人类免疫缺陷病毒1型(HIV-1)Pol区基因型耐药检测结果的差异,并分析DBS样品用于HIV-1基因型耐药检测的可行性。方法采集44例HIV-1感染者治疗前静脉全血,分别制备全血DBS样品和血浆样品,提取RNA,检测病毒载量。采用逆转录PCR(RT-PCR)扩增Pol区基因序列,对PCR产物进行Sanger测序,采用Sequencher 5.4.5软件对序列进行清理和拼接,采用BioEdit 7.2软件对参考株序列和样品序列进行比对、系统进化树分析及基因型耐药分析。结果治疗前44例血浆样品检出率100.0%,DBS样品检出30例,检出率为68.2%;24例血浆样品平均病毒载量达到5.02×10^(5)IU/mL,中位数为1.76×10^(5)IU/mL,DBS样品平均病毒载量为1.46×10^(3)IU/mL,中位数为7.95×10^(2)IU/mL;44例患者HIV-1亚型主要为流行重组株(CRF)07-BC(24/44)、CRF01-AE(16/44);血浆和DBS样品序列相似值100%26例(26/30),相似值99%3例(3/30),相似值97%1例(1/30),其中有6例发生不同程度的耐药突变,DBS样品耐药结果与血浆符合率100%,但在其他位点的突变存在差异。结论治疗前全血DBS样品耐药结果及序列与血浆样品具有高度的一致性,全血DBS样品可用于耐药性检测、HIV-1亚型分析,但检出率比血浆低。 展开更多
关键词 干血斑 人类免疫缺陷病毒1 病毒载量 基因型耐药 亚型
下载PDF
Human mpox co-infection with advanced HIV-1 and XDR-TB in a MSM patient previously vaccinated against smallpox:A case report
20
作者 Yuan Fang Fuchun Wang +12 位作者 Taiyi Jiang Junyi Duan Tao Huang Hao Liu Lin Jia Han Jia Benyong Yan Mei Zhang Wen Wang Caiping Guo Lifeng Liu Yuening Zhang Tong Zhang 《Biosafety and Health》 CAS CSCD 2024年第3期186-190,共5页
Mpox is a zoonotic infectious disease caused by the mpox virus(MPXV).Historically,the majority of mpox cases have been documented in Central Africa.However,since May 2022,there has been a notable rise in reported case... Mpox is a zoonotic infectious disease caused by the mpox virus(MPXV).Historically,the majority of mpox cases have been documented in Central Africa.However,since May 2022,there has been a notable rise in reported cases from regions beyond Africa.Currently,over 110 countries spanning Europe,North America,South America,Asia,and other territories have reported mpox infections.This report details a case involving a patient who identifies as a man who has sex with men(MSM)and is concurrently infected with MPXV,human immunodeficiency virus type 1(HIV-1),Pneumocystis jiroveci,as well as extensively drug-resistant tuberculosis(XDR-TB).This patient had also received a vaccination for smallpox in the past.Additionally,we provide photographic documentation charting the progression of dermatological manifestations associated with mpox.This case highlights the significance of sexual intercourse as a crucial mode of transmission for mpox.The rapid and widespread dissemination of the MPXV across various regions,especially among MSM communities,underscores the importance of enhancing preventive education efforts targeted at high-risk populations. 展开更多
关键词 Mpox Mpox virus(MPXV) human immunodeficiency virus type 1 (HIV-1)Extensively drug-resistant tuberculosis(XDR-TB)
原文传递
上一页 1 2 22 下一页 到第
使用帮助 返回顶部